Skip to main content
SpringerLink
Log in
Book cover

Reducing Breast Cancer Risk in Women pp 91–101Cite as

Trial of Tamoxifen Therapy for Protection

  • Chapter

  • 51 Accesses

Part of the book series: Developments in Oncology ((DION,volume 75))

Abstract

The evolution of breast cancer is likely to be promoted by estrogen acting together with other hormones [1]. Since promotion steps in cancer development are often reversible, it has been proposed that the progression of breast cancer may be suppressed by giving an antiestrogen for a prolonged period.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Howell, A. (1989). Clinical evidence for the involvement of oestrogen in the development and progression of breast cancer. Proc. Roy. Soc. Edin., 95B, 49–57.

    Google Scholar 

  2. Gray, R. (1993). Tamoxifen; how boldly to go where no women have gone before. J. Natl Cancer Inst., 85, 1358–1360.

    Article  CAS  Google Scholar 

  3. Fugh-Berman, A., Epstein, S. (1992) Tamoxifen; disease prevention or disease substitution. Lancet, 340, 1143–1145.

    Article  PubMed  CAS  Google Scholar 

  4. Stoll, B.A. (1983). Intermittent anti-estrogen therapy in advanced breast cancer. Cancer Treat. Rep., 67, 98–99.

    PubMed  CAS  Google Scholar 

  5. Sunderland, M.C., Osborne, C.K. (1991). Tamoxifen in premenopausal patients with metastatic breast cancer; a review. J. Clin Oncol., 9,1283–1297.

    PubMed  CAS  Google Scholar 

  6. Early Breast Cancer Trialists Collaborative Group (1988). Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28, 896 women. N. Engl. J. Med., 319, 1681–1692.1.

    Article  Google Scholar 

  7. Scottish Cancer Trials Office, MRC Edinburgh (1987). Adjuvant tamoxifen in the management of operable breast cancer; the Scottish trial. Lancet, 2,171–175.

    Google Scholar 

  8. Palshof, T., Mouridsen H.T., Daehnfeldt, J.L. (1985). Adjuvant endocrine therapy in pre and postmenopausal women with operable breast cancer. Rev. Endoc. Rel. Cancer, 17, (Suppl.), 43–50.

    Google Scholar 

  9. Cummings, F.J., Gray, R., Davis, T.E. (1986). Tamoxifen versus placebo. Double blind adjuvant trial in elderly women with Stage 2 breast cancer. In Proceedings of the NJH Consensus Development Conference on Adjuvant Chemotherapy and Endocrine Therapy for Breast Cancer, Bethesda, Maryland, 119–123.

    Google Scholar 

  10. Rutqvist, L.E., Cedermark, B., Glas, U. (1987). The Stockholm trial on adjuvant tamoxifen in early breast cancer. Breast Cancer Res. Treat, 10, 255–266.

    Article  PubMed  CAS  Google Scholar 

  11. Pritchard, K. J., Meakin, J.W., Boyd, N.F. (1987). Adjuvant tamoxifen in postmenopausal women with axillary node positive breast cancer; an update. In Salmon, S.E. (ed.), Adjuvant Therapy of Cancer, Grune & Stratton, New York, 391–400.

    Google Scholar 

  12. CRC Adjuvant Breast Trial Working Party (1988). Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. Br. J. Cancer, 57, 604–607.

    Article  Google Scholar 

  13. Nolvadex Adjuvant Trial Organisation (1988). Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br. J. Cancer, 57, 608–611.

    Article  Google Scholar 

  14. Fisher, B., Costantino, J., Redmond, C. et al. (1989). A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor positive tumors. N. Engl J. Med., 320,479–484.

    Article  PubMed  CAS  Google Scholar 

  15. Nayfield, S.G., Karp, J.E., Ford, L.G., Dorr, F.A., Kramer, B.S. (1991). Potential role of tamoxifen in prevention of breast cancer. J. Natl. Cancer Inst., 83, 1450–1459.

    Article  PubMed  CAS  Google Scholar 

  16. Wattenberg, L.W. (1993). Prevention therapy; basic science and the resolution of the cancer problem. Cancer Res., 53, 5890–5896.

    PubMed  CAS  Google Scholar 

  17. Jordan, V.C., Gottandis, M.M., Robinson, S.P. (1989). Immune-deficient animals to study hormone dependent breast and endometrial cancer. J. Steroid Biochem., 34, 169–176.

    Article  PubMed  CAS  Google Scholar 

  18. Gottardis, M.M., Jordan, V.C. (1987). The antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced ratmammary carcinoma model. Cancer Res., 47,4020–4024.

    PubMed  CAS  Google Scholar 

  19. Chlebowski, R.T., Butler, J., Nelson, A., Lillington, L. (1993). Breast cancer chemoprevention. Cancer, 72, 1032–1037.

    Article  PubMed  CAS  Google Scholar 

  20. Jones, A.L., Powles, T.J., Treleaven, J.G. et al. (1992). Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women. Br. J. Cancer, 66, 744–747.

    Article  PubMed  CAS  Google Scholar 

  21. Rutqvist, L.E., Mattson, A. (1993). Cardiac and thromboembolic morbidity among postmenopausal women with early stage breast cancer in a randomized trial of adjuvant tamoxifen. J. Natl. Cancer Inst., 85, 1398–1406.

    Article  PubMed  CAS  Google Scholar 

  22. Hard, G.C., Williams, G.M., Iatropoulos, M.J. (1993). Tamoxifen and liver cancer. Lancet, 342, 444 445.

    Google Scholar 

  23. Pavlidis, N.A., Petris, C., Briassoulis, E. et al. (1992). Clear evidence that long term, low dose tamoxifen treatment can induce ocular toxicity. Cancer, 69, 2961–2964.

    Article  PubMed  CAS  Google Scholar 

  24. Magriples, U., Naftalin, F., Schwartz, P.E., Carcangiu, M.L. (1993). High grade endometrial cancer in tamoxifen-treated breast cancer patients. J. Clin. Oncol, 11,485–490.

    PubMed  CAS  Google Scholar 

  25. Van Leeuwen, F.E., Benraadt, J., Coebergh, J.W.W. et al. (1994) Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet, 343,448–452.

    Article  PubMed  Google Scholar 

  26. Neven, P. (1993). Tamoxifen and endometrial lesions. Lancet, 342, 452.

    Article  PubMed  CAS  Google Scholar 

  27. Powles, T.J., Tillyer, C.R., Jones, A.L. et al. (1990). Prevention of breast cancer with tamoxifen; an update on the Royal Marsden Hospital Pilot Programme. Eur. J. Cancer, 26, 680–684.

    Article  PubMed  CAS  Google Scholar 

  28. Cuzick, J., Allen, D., Baum, M. et al. (1993). Long term effects of tamoxifen; biological effects of Tamoxifen Working Party. Eur. J. Cancer, 29A, 15–21.

    Article  Google Scholar 

  29. Fisher, B., Redmond, C. (1991). New perspective on cancer of the contralateral breast; a marker for assessing tamoxifen as a preventive agent. J. Natl. Cancer Inst., 83, 1278–1280. 22.

    Article  PubMed  CAS  Google Scholar 

  30. Redmond, C.K., Wickerham, D.L., Cronin, W. (1993). The NSABP Breast Cancer Prevention Trial; a progress report. Proc. ASCO, 12, 69.

    Google Scholar 

  31. Gail, M.H., Brinton, L.A., Byar, D.P. et al (1989). Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl. Cancer Inst., 81, 1879–1886.

    Article  PubMed  CAS  Google Scholar 

  32. News (1993). Breast cancer chemoprevention trials launched in Europe. Ann. Oncol., 4,2.

    Google Scholar 

  33. News (1993). Breast cancer prevention study initiated in Italy. J. Natl. Cancer Inst., 84,1555–1556.

    Google Scholar 

  34. News (1993). UK prevention trial gets go-ahead and expands to other countries. Ann. Oncol, 4,707–708.

    Google Scholar 

  35. News (1993). European tamoxifen studies moving ahead. J. Natl. Cancer Inst., 85,145–1451.

    Google Scholar 

  36. Jordan, V.C. (1993). How safe is tamoxifen? Br. Med. J., 307, 1371–1372.

    Article  CAS  Google Scholar 

  37. Paterson, H.G., Geggie, P.H.S. (1993). Can tamoxifen prevent breast cancer?Can. Med. Assoc. J., 148,142–143.

    Google Scholar 

  38. Lantos, J. (1993). Informed consent; the whole truth for patients. Cancer, 72, 2811–2815.

    Article  PubMed  CAS  Google Scholar 

  39. DeFriend, D.J., Howell, A., Nicholson, R.I. et al (1994). Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res., 54,408–414.

    PubMed  CAS  Google Scholar 

  40. McCormick, D., Moon, R. (1986). Retinoid-tamoxifen interaction in mammary cancer chemoprevention. Cancinogenesis, 7, 193–196.

    Article  CAS  Google Scholar 

Download references

Authors
  1. Basil A. Stoll
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Oncology Department, St. Thomas’ Hospital, London, UK

    Basil A. Stoll (Honorary Consulting Physician, Consultant) (Honorary Consulting Physician, Consultant)

  2. Joint Breast Clinic, Royal Free Hospital, London, UK

    Basil A. Stoll (Honorary Consulting Physician, Consultant) (Honorary Consulting Physician, Consultant)

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Stoll, B.A. (1995). Trial of Tamoxifen Therapy for Protection. In: Stoll, B.A. (eds) Reducing Breast Cancer Risk in Women. Developments in Oncology, vol 75. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-0489-0_10

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-0489-0_10

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-4219-2

  • Online ISBN: 978-94-011-0489-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation